Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | PMC:PMC8760827 | DOI:10.1186/s12981-022-00428-5 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | PMC:PMC8760827 | DOI:10.1186/s12981-022-00428-5 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | PMC:PMC8760827 | DOI:10.1186/s12981-022-00428-5 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | PMC:PMC8760827 | DOI:10.1186/s12981-022-00428-5 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | PMC:PMC8760827 | DOI:10.1186/s12981-022-00428-5 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed effica... (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 15, 2022 Category: Infectious Diseases Authors: Nolwenn Hall, Clotilde Allavena, Christine Katlama, Alexandra Jobert, Jean-Michel Molina, Eric Cua, Firouz é Bani-Sadr, Laurent Hocqueloux, Claudine Duvivier, Dominique Merrien, Hitoto Hikombo, Elisabeth André-Garnier, Aurélie Gaultier and François Ra Tags: Research Source Type: research
Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam
AIDS Research and Human Retroviruses, Ahead of Print. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - January 13, 2022 Category: Infectious Diseases Authors: Cecilia M. Shikuma Thuy Le Thao Vu Phuong Glen M. Chew Van Vinh Chau Nguyen Trieu Ly Vo Chathura Siriwardhana Dominic Chow Hayk Ghukasyan Nath Limpruttidham Thomas Premeaux Louie Mar Gangcuangco Robert Paul Lishomwa C. Ndhlovu Source Type: research
Integrase Inhibitors Use for HIV Infection in Pregnancy
AbstractPurpose of ReviewThere are important unmet needs regarding HIV infection, particularly in vulnerable population, such as pregnant women and the safety and efficacy of antiretrovirals to them and their newborn. HIV integrase inhibitor agents are among the preferred antiretrovirals in most guidelines worldwide. The purpose of this review is to evaluate their safety and efficacy in that specific population.Recent FindingsAn increased importance it is being paid to this issue. However, only recently and just a few studies have been conducted trying to evaluate and compare these drugs with other agents such as efavirenz...
Source: Current Infectious Disease Reports - January 1, 2022 Category: Infectious Diseases Source Type: research
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use
Conclusions:
This patient-focused process produced health literate instructions for preparing and administering an antiretroviral for neonatal use with complex dosing requirements. Testing demonstrated that lay users with a range of health literacy levels were able to accurately mix, measure and administer the product. This process demonstrates how a neonatal medication can be optimized for use through collaboration between the infectious disease expert community and a manufacturer. (Source: The Pediatric Infectious Disease Journal)
Source: The Pediatric Infectious Disease Journal - December 15, 2021 Category: Infectious Diseases Tags: HIV Reports Source Type: research
Immunologic Change over 72 Weeks following Raltegravir- vs Efavirenz-based Therapy in HIV/HCV co-infected Individuals in Vietnam
CONCLUSIONS: The initiation of ART in HIV/HCV co-infected individuals is associated with incomplete improvement in monocyte and T cell immune activation and exhaustion, which was associated with some corresponding improvement in liver fibrosis.PMID:34861767 | DOI:10.1089/AID.2021.0076 (Source: Cell Research)
Source: Cell Research - December 4, 2021 Category: Cytology Authors: Cecilia Shikuma Thuy Le Thao Vu Phuong Glen M Chew Van Vinh Chau Nguyen Trieu Ly Vo Chathura Siriwardhana Dominic Chow Hayk Ghukasyan Nath Limpruttdham Thomas Premeaux Louie Mar A Gangcuangco Robert H Paul Lishomwa C Ndhlovu Source Type: research
Molecules, Vol. 26, Pages 7129: Identification of Influenza PAN Endonuclease Inhibitors via 3D-QSAR Modeling and Docking-Based Virtual Screening
ing Liu
Chun Hu
Structural and biochemical studies elucidate that PAN may contribute to the host protein shutdown observed during influenza A infection. Thus, inhibition of the endonuclease activity of viral RdRP is an attractive approach for novel antiviral therapy. In order to envisage structurally diverse novel compounds with better efficacy as PAN endonuclease inhibitors, a ligand-based-pharmacophore model was developed using 3D-QSAR pharmacophore generation (HypoGen algorithm) methodology in Discovery Studio. As the training set, 25 compounds were taken to generate a significant pharmacophore model. The selected...
Source: Molecules - November 25, 2021 Category: Chemistry Authors: Chao Zhang Junjie Xiang Qian Xie Jing Zhao Hong Zhang Erfang Huang Pangchui Shaw Xiaoping Liu Chun Hu Tags: Article Source Type: research
Inflammatory biomarkers and soft tissue changes among patients commencing second-line antiretroviral therapy after first-line virological failure
Conclusion:
Inflammatory biomarkers provide important mechanistic insights into the pathogenesis of limb fat and lean mass changes independently of ART. (Source: AIDS)
Source: AIDS - November 5, 2021 Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial
Conclusions:
Detectable VVL in pregnant women with undetectable/nonquantifiable PVL while receiving ART was rare and not associated with perinatal HIV transmission. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - November 4, 2021 Category: Infectious Diseases Tags: Prevention Research Source Type: research
Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation
Background:
We have previously shown that the initiation of antiretroviral therapy (ART) is associated with a decrease in skeletal muscle density (greater fat accumulation), suggesting that gains in lean body mass seen in many ART studies may reflect gains in low quality, fatty muscle. Here, we explore whether skeletal muscle density and area are associated with markers of inflammation and immune activation.
Methods:
ART-naïve people with HIV were randomized to raltegravir or ritonavir-boosted atazanavir or darunavir, each with tenofovir disoproxil fumarate/emtricitabine. Abdominal computed tomography scans fro...
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - November 4, 2021 Category: Infectious Diseases Tags: Clinical Science Source Type: research
Molecules, Vol. 26, Pages 5672: π–π Noncovalent Interaction Involving 1,2,4- and 1,3,4-Oxadiazole Systems: The Combined Experimental, Theoretical, and Database Study
dim Boyarskiy
A series of N-pyridyl ureas bearing 1,2,4- (1a, 2a, and 3a) and 1,3,4-oxadiazole moiety (1b, 2b, 3b) was prepared and characterized by HRMS, 1H and 13C NMR spectroscopy, as well as X-ray diffraction. The inspection of the crystal structures of (1–3)a,b and the Hirshfeld surface analysis made possible the recognition of the (oxadiazole)···(pyridine) and (oxadiazole)···(oxadiazole) interactions. The presence of these interactions was confirmed theoretically by DFT calculations, including NCI analysis for experimentally determined crystal structures as well as QTAIM analysis for optimized equilibrium...
Source: Molecules - September 18, 2021 Category: Chemistry Authors: Sergey Baykov Alexander Mikherdov Alexander Novikov Kirill Geyl Marina Tarasenko Maxim Gureev Vadim Boyarskiy Tags: Article Source Type: research
